4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]- phenol hydrochloride (SIB- 1553A): A novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors

Journal of Medicinal Chemistry

Volumn 42, Issue 10, 1999, Pages 1684-1686

  Vernier, Jean Michel ^a   El Abdellaoui, Hassan ^a   Holsenback, Heather ^a   Cosford, Nicholas D P ^a   Bleicher, Leo ^a   Barker, Geoffrey ^a   Bontempi, Bruno ^a   Chavez Noriega, Laura ^a   Menzaghi, Frederique ^a   Rao, Tadimeti S ^a   Reid, Richard ^a   Sacaan, Aida I ^a   Suto, Carla ^a   Washburn, Mark ^a   Lloyd, G Kenneth ^a   McDonald, Ian A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; AGONIST; ALZHEIMER DISEASE; ANIMAL TISSUE; BRAIN CORTEX; COGNITION; DOPAMINE RELEASE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIPPOCAMPUS; HUMAN; HUMAN CELL; LETTER; NONHUMAN; NORADRENALIN RELEASE; PRESYNAPTIC NERVE; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING, COMPETITIVE; CELL LINE; CEREBRAL CORTEX; HUMANS; NEURONS; NICOTINIC AGONISTS; NOOTROPIC AGENTS; OOCYTES; PATCH-CLAMP TECHNIQUES; PHENOLS; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; TRANSFECTION; XENOPUS;

EID: 0033587123     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990035d     Document Type: Letter

References (33)

1. (a) McDonald, I. A.; Cosford, N. D. P.; Vernier, J.-M. Nicotinic acetylcholine receptors: molecular biology, chemistry and pharmacology. Annu. Rep. Med. Chem. 1995, 30, 41-50.
2. (b) McDonald, I. A.; Vernier, J.-M.; Cosford, N. D. P.; Corey-Naeve, J. Neuronal nicotinic acetylcholine receptor agonists. Curr. Pharm. Des. 1996, 2, 357-366.
3. Greenamyre, J. T.; Maragos, W. F. Neurotransmitter receptors in Alzheimer disease. Cerebrovasc. Brain Meta. Rev. 1993, 61-94.
4. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J. Neurochem. 1986, 47, 1948-1954.
5. 3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 1986, 72, 115-119.
6. (c)Shimohama, S.; Taniguchi, T.; Fujiwara, M.; Kameyama, M. Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J. Neurochem. 1986, 46, 288-293.
7. (d) Whitehouse, P. J.; Martino, A. M.; Antuono, P. G.; Lowenstein, P. R.; Coyle, J. T.; Price, D. L.; Kellar, K. J. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 1986, 371, 146-151.
8. 3H]-Methylcarbamylcholine binding sites in the rat and human brain: relationship to functional nicotinic autoreceptors and alterations in Alzheimer's disease. Prog. Brain Res. 1989, 79, 345-352.
9. (b) Araujo, D. M.; Lapchak, P. A.; Robitaille, Y.; Gauthier, S.; Quirion, R. Differential alternation of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J. Neurochem. 1988, 50, 1914-1923.
10. (c) Perry, E. K.; Perry, R. H.; Smith, C. J.; Dick, D. J.; Candy, J. M.; Edwardson, J. A.; Fairbairn, A.; Blessed, G. Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases. J. Neurol. Neurosurg. Psychiatry 1987, 50, 806-809.
11. (d) Rinne, J. O.; Myllykyla, T.; Lonnberg, P.; Marjamaki, P. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res. 1991, 547, 167-170.
12. Sugaya, K.; Giacobini, E.; Chiappinelli, V. A. Nicotinic acetylcholine receptor subtypes in human frontal cortex: changes in Alzheimer's disease. J. Neurosci. Res. 1990, 27, 349-359.
13. Itoh, A.; Nitta, A.; Nadai, M.; Nishimura, K.; Hirose, M.; Hasegawa, T.; Nabeshima, T. Dysfunction of cholinergic and dopaminergic neuronal systems in β-amyloid protein-infused rat. J. Neurochem. 1996, 66, 1113-1117.
14. Sahakian, B.; Jones, G.; Levy, R.; Gray, J.; Warburton, D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzeimer type. Br. J. Psychiatry 1989, 154, 797-800.
15. Newhouse, P. A.; Potter, A.; Levin, E. D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging 1997, 11, 206-228.
16. Shytle, R. D.; Borlongan, C. V.; Cahill, D. W.; Sanberg, P. R. Evidence for the neuroprotective actions of nicotine in an in vivo model of excitotoxicity. Med. Chem. Res. 1996, 555-561.
17. Cosford, N. D. P.; Bleicher, L.; Herbaut, A.; McCallum, J. S.; Vernier, J.-M.; Dawson, H.; Whitten, J. P.; Adams, P.; Chavez-Noriega, L.; Correa, L. D.; Mahaffy, L. S.; Menzaghi, F.; Rao, T. S.; Reid, R.; Sacaan, A. I.; Santori, E.; Stauderman, K. A.; Whelan, K.; Lloyd, G. K.; McDonald, I. A. (S)-(-)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): A novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. 1996, 39, 3235-3237.
18. Lee, T. S.; Hou, X. Nicotine is hazardous to your heart. Chest 1996, 109, 584-585.
19. Garvey, D. S.; Wasicak, J. T.; Decker, M. W.; Brioni, J. D.; Buckley, M. J.; Sullivan, J. P.; Carrera, G. M.; Holladay, M. W.; Arneric, S. P.; Williams, M. Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities. J. Med. Chem. 1994, 37, 1055-1059.
20. Lin, N.-H.; Gunn, D. E.; Ryther, K. B.; Garvey, D. S.; Donnelly-Roberts, D. L.; Decker, M. W.; Brioni, J. D.; Buckley, M. J.; Rodrigues, A. D.; Marsh, K. G.; Anderson, D. J.; Buccaftisco, J. J.; Prendergast, M. A.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. J. Med. Chem. 1997, 40, 385-390.
21. De Fiebre, C. M.; Meyer, E. M.; Henry, J. C.; Muraskin, S. I.; Kern, W. R.; Papke, R. L. Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethyl-aminocinnamylidine derivative is a selective agonist at neuronalnicotinic α7/α-bungarotoxin receptor subtypes. Mol. Pharmacol. 1995, 47, 164-171.
22. Cosford, N. D. P.; Vernier, J.-M.; McDonald, I. A. Unpublished data.
23. D values reported in the literature. Ebnöther, A.; Weber, H. P.; Meier, W. Helv. Chim. Acta 1976, 59, 2462-2468.
24. The isomers were analyzed by normal-phase HPLC with a Daicel Chiralpak AD column (10 mm, 250 × 4.6 mm) at room temperature, using a mobile phase consisting of heptane, ethanol, and trifluoroacetic acid (90:10:0.2) at 1.0 mL/min. Detection was carried out at 254 nm.
25. (a) Stauderman, K. A.; Mahaffy, L. S.; Akong, M.; Veliçelebi, G.; Chavez-Noriega, L. E.; Crona, J. H.; Johnson, E. C.; Elliott, K. J.; Gillespie, A.; Reid, R. T.; Adams, P.; Harpold, M. M.; Corey-Naeve, J. Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations α2β4, α3β4 and α4β4 stably expressed in HEK293 cells. J. Pharmacol. Exp. Ther. 1998, 284, 777-789.
26. Compound 5 was tested at a saturated concentration with current responses (elicited at -60 mV) normalized to the response produced by a saturating concentration of nicotine (for α2β4, α3β4, α4β2, and α4β4), acetylcholine (α2β2 and α7), and DMPP (α3β2) applied to the same oocytes.
27. Chavez-Noriega, L. E.; Crona, J. H.; Washburn, M. S.; Urrutia, A.; Elliott, K. J.; Johnson, E. C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4 and hα7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1997, 280, 346-456.
28. Washburn, M. S.; Chavez-Noriega, L. E.; Crona, J. H.; Vernier, J.-M.; Johnson, E. Electrophysiological characterization of SIB-1553A activity on recombinant human nicotinic receptors express in Xenopus oocytes and HEK-293 cells. Soc. Neurosci. Abstr. 1997, 23, 1198.
29. Flores, C. M.; Rogers, S. W.; Pabreza, L. A.; Wolfe, B. B.; Kellar, K. J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. 1992, 41, 31-37.
30. Sacaan, A. I.; Dunlop, J. L.; Lloyd, G. K. Pharmacological characterization of neuronal nicotinic acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. J. Pharmacol. Exp. Ther. 1995, 274, 224-230.
31. Reid, R. T.; Sacaan, A. I.; Adams, P. B.; Correa, L. D.; Santori, E. M.; McDonald, I. A.; Lloyd, G. K.; Rao, T. S. Pharmacological characterization of SIB-1553A, a novel subtype selective neuronal nicotinic acetylcholine receptor agonist. Soc. Neurosci. Abstr. 1997, 23, 477.17.
32. Bontempi, B.; Whelan, K. T.; Risbrough, V. B.; Joppa, M. A.; Kille, N.; Buccafusco, J. J.; Menzaghi, F.; Lloyd, G. K. SIB-1553A, a novel nAChR agonist with cognitive enhancing properties in aged rodents and nonhuman primates: effects on various memory forms. Soc. Neurosci. Abstr. 1997, 23, 477.15.
33. Menzaghi, F.; Joppa, M. A.; Reid, R. T.; Sacaan, A. I.; Bontempi, B.; Whelan, K. T.; Santori, E. M.; Risbrough, V. B.; Lloyd, G. K. Memory deficits associated with cholinergic dysfunctions: reversal by SIB-1553A a novel nAChR agonist. Soc. Neurosci. Abstr. 1997, 23, 477.16.